Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase bowel disease drug candidate. Months after midphase data sent Prometheus’ stock spiraling upward, Merck has agreed ...
Jeff Bezos is stepping back into direct leadership with a powerful new artificial intelligence venture, and the scale of the project has revived concerns about concentrated global influence. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results